149 related articles for article (PubMed ID: 17149790)
1. Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity.
Kanerva A; Raki M; Ranki T; Särkioja M; Koponen J; Desmond RA; Helin A; Stenman UH; Isoniemi H; Höckerstedt K; Ristimäki A; Hemminki A
J Gene Med; 2007 Jan; 9(1):3-9. PubMed ID: 17149790
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
[TBL] [Abstract][Full Text] [Related]
3. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
[TBL] [Abstract][Full Text] [Related]
4. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
[TBL] [Abstract][Full Text] [Related]
5. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
[TBL] [Abstract][Full Text] [Related]
6. Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir.
Diaconu I; Cerullo V; Escutenaire S; Kanerva A; Bauerschmitz GJ; Hernandez-Alcoceba R; Pesonen S; Hemminki A
J Gene Med; 2010 May; 12(5):435-45. PubMed ID: 20440754
[TBL] [Abstract][Full Text] [Related]
7. Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter.
Hakkarainen T; Rajecki M; Sarparanta M; Tenhunen M; Airaksinen AJ; Desmond RA; Kairemo K; Hemminki A
Clin Cancer Res; 2009 Sep; 15(17):5396-403. PubMed ID: 19706820
[TBL] [Abstract][Full Text] [Related]
8. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
[TBL] [Abstract][Full Text] [Related]
9. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
Lam JT; Kanerva A; Bauerschmitz GJ; Takayama K; Suzuki K; Yamamoto M; Bhoola SM; Liu B; Wang M; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
J Gene Med; 2004 Dec; 6(12):1333-42. PubMed ID: 15493039
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
[TBL] [Abstract][Full Text] [Related]
11. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity.
Barton KN; Paielli D; Zhang Y; Koul S; Brown SL; Lu M; Seely J; Kim JH; Freytag SO
Mol Ther; 2006 Feb; 13(2):347-56. PubMed ID: 16290236
[TBL] [Abstract][Full Text] [Related]
12. A truncated minimal-E1a gene with potency to support adenoviral replication mediates antitumor activity by down-regulating Neu expression and preserving Rb function.
Fang L; Huang Y; Hu X; Sun L; He X; Hu H; Pu Y; Cao X; Luo H; Pan S; Gu J; Su C
Chem Biol Interact; 2009 Sep; 181(1):1-7. PubMed ID: 19523934
[TBL] [Abstract][Full Text] [Related]
13. Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site.
Carette JE; Graat HC; Schagen FH; Abou El Hassan MA; Gerritsen WR; van Beusechem VW
J Gene Med; 2005 Aug; 7(8):1053-62. PubMed ID: 15756711
[TBL] [Abstract][Full Text] [Related]
14. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
15. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Raki M; Särkioja M; Desmond RA; Chen DT; Bützow R; Hemminki A; Kanerva A
Gynecol Oncol; 2008 Jan; 108(1):166-72. PubMed ID: 17950450
[TBL] [Abstract][Full Text] [Related]
17. A double-regulated oncolytic adenovirus with improved safety for adenocarcinoma therapy.
Wei N; Fan JK; Gu JF; He LF; Tang WH; Cao X; Liu XY
Biochem Biophys Res Commun; 2009 Oct; 388(2):234-9. PubMed ID: 19653996
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic adenoviruses for the treatment of brain tumors.
Gomez-Manzano C; Fueyo J
Curr Opin Mol Ther; 2010 Oct; 12(5):530-7. PubMed ID: 20886384
[TBL] [Abstract][Full Text] [Related]
19. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J
Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740
[TBL] [Abstract][Full Text] [Related]
20. Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models.
Wu CL; Shieh GS; Chang CC; Yo YT; Su CH; Chang MY; Huang YH; Wu P; Shiau AL
Clin Cancer Res; 2008 Feb; 14(4):1228-38. PubMed ID: 18281558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
